TGFB1 and neoplasm: Furthermore, recognizing the important role of TGF-β and PD-L1 in tumor resistance, a bifunctional fusion protein blocking simultaneously the TGF-β and PD-1 pathway has been developed (M7824), enabling immune cell infiltration and tumor regression in preclinical studies, moving into first clinical trials [48].